The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway
Biomolecules · 21.06.2024 · 14 (7) · 738
DOI: 10.3390/biom14070738 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 21.06.2024. Verfasst von Haoming Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, Ch…. Hauptthemen laut MEDLINE: Cyclopentanes, Pyrimidines, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
(1) Background: The neddylation pathway assumes a pivotal role in the initiation and progression of cancer. MLN4924, a potent small-molecule inhibitor of the NEDD8-activating enzyme (NAE), effectively intervenes in the early stages of the neddylation pathway. By instigating diverse cellular responses, such as senescence and apoptosis in cancer cells, MLN4924 also exerts regulatory effects on non-malignant cells within the tumor microenvironment (TME) and tumor virus-infected cells, thereby impeding the onset of tumors. Consequently, MLN4924 has been widely acknowledged as a potent anti-cancer drug. (2) Recent findings: Nevertheless, recent findings have illuminated additional facets of the neddylation pathway, revealing its active involvement in various biological processes detrimental to the survival of cancer cells. This newfound understanding underscores the dual role of MLN4924 in tumor therapy, characterized by both anti-cancer and pro-cancer effects. This dichotomy is herein referred to as the “double-edged effects” of MLN4924. This paper delves into the intricate relationship between the neddylation pathway and cancer, offering a mechanistic exploration and analysis of the causes underlying the double-edged effects of MLN4924—specifically, the accumulation of pro-cancer neddylation substrates. (3) Perspectives: Here, the objective is to furnish theoretical support and novel insights that can guide the development of next-generation anti-cancer drugs targeting the neddylation pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China.
- Department of Immunology, School of Basic Medical Sciences, Chengdu Medical College, Chengdu 610500, China.
- Department of Spine Surgery, People's Hospital of Longhua, Affiliated Hospital of Southern Medical University, Shenzhen 518109, China.
ORCID-Profile: Shun Li, Liling Tang
Förderung
- the Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Shenzhen Science and Technology Program
- Shenzhen Longhua District Science and Technology Innovation Fund Project
- Chengdu Medical College - Chengdu Seventh Hospital Clinical Science Research innovation team foundation
Zitieren
APA
Tang, H., Pang, X., Li, S., & Tang, L. (2024). The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway. Biomolecules, 14(7), 738. https://doi.org/10.3390/biom14070738
Vancouver
Tang H, Pang X, Li S, Tang L. The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway. Biomolecules. 2024;14(7):738. doi:10.3390/biom14070738
BibTeX
@article{Tang2024,
author = {Tang, Haoming and Pang, Xin and Li, Shun and Tang, Liling},
title = {The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {7},
pages = {738},
doi = {10.3390/biom14070738}
}
EUVIMED